SG11202109563WA - Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction - Google Patents
Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunctionInfo
- Publication number
- SG11202109563WA SG11202109563WA SG11202109563WA SG11202109563WA SG11202109563WA SG 11202109563W A SG11202109563W A SG 11202109563WA SG 11202109563W A SG11202109563W A SG 11202109563WA SG 11202109563W A SG11202109563W A SG 11202109563WA SG 11202109563W A SG11202109563W A SG 11202109563WA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- pathway inhibitors
- chronic lung
- lung allograft
- allograft dysfunction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814085P | 2019-03-05 | 2019-03-05 | |
| PCT/US2020/021088 WO2020181034A1 (en) | 2019-03-05 | 2020-03-05 | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109563WA true SG11202109563WA (en) | 2021-09-29 |
Family
ID=69941525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109563WA SG11202109563WA (en) | 2019-03-05 | 2020-03-05 | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11406640B2 (https=) |
| EP (2) | EP4691567A3 (https=) |
| JP (2) | JP2022524997A (https=) |
| KR (1) | KR20210137087A (https=) |
| CN (1) | CN114007621A (https=) |
| AU (1) | AU2020232757B2 (https=) |
| CA (1) | CA3132371A1 (https=) |
| EA (1) | EA202192426A1 (https=) |
| IL (1) | IL285999B2 (https=) |
| MA (1) | MA55201A (https=) |
| MX (2) | MX2021010545A (https=) |
| PH (1) | PH12021552130A1 (https=) |
| SG (1) | SG11202109563WA (https=) |
| UA (1) | UA130579C2 (https=) |
| WO (1) | WO2020181034A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3837258T3 (fi) | 2018-09-04 | 2024-05-27 | Theravance Biopharma R&D Ip Llc | Dimetyyliaminoatsetidiiniamideja jak-estäjinä |
| UA127328C2 (uk) | 2018-09-04 | 2023-07-19 | Тереванс Байофарма Ар Енд Ді Айпі, Елелсі | 5-7-членні гетероциклічні аміди як інгібітори jak |
| KR20210084512A (ko) | 2018-10-29 | 2021-07-07 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제로서 2-아자비시클로 헥산 화합물 |
| CA3117969A1 (en) | 2018-10-31 | 2020-05-07 | Incyte Corporation | Combination therapy for treatment of hematological diseases |
| WO2020181034A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| TW202144343A (zh) | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| TW202237083A (zh) * | 2021-01-11 | 2022-10-01 | 美商英塞特公司 | 包含ｊａｋ路徑抑制劑及ｒｏｃｋ抑制劑之組合療法 |
| EP4359402B1 (en) | 2021-06-25 | 2026-03-11 | Theravance Biopharma R&D IP, LLC | Imidazolo indazole compounds as jak inhibitors |
| KR102952944B1 (ko) | 2021-10-15 | 2026-04-14 | 주식회사 엘지에너지솔루션 | 용접봉 체결 방법 및 이에 의해 용접봉이 수직으로 체결된 용접 장치 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| US20070219223A1 (en) | 2006-03-07 | 2007-09-20 | Endacea, Inc. | Compositions and methods for treating respiratory disorders |
| US8058227B2 (en) | 2006-10-03 | 2011-11-15 | Medical University Of South Carolina | Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD |
| KR20150036210A (ko) | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| EP2684564A1 (en) | 2008-04-17 | 2014-01-15 | Sanofi | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or in the prevention of atrial fibrillation |
| AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| RU2711869C3 (ru) | 2009-12-01 | 2022-02-02 | Эббви Инк. | Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk |
| EP3354652B1 (en) | 2010-03-10 | 2020-05-06 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| RU2013120966A (ru) | 2010-10-08 | 2014-11-20 | Эббви Инк. | ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ |
| PE20140146A1 (es) | 2010-11-19 | 2014-02-06 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| CN103797010B (zh) | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| HRP20250965T1 (hr) | 2012-06-15 | 2025-10-10 | Sun Pharmaceutical Industries, Inc. | Deuterirani derivati ruksolitiniba |
| WO2014028756A1 (en) | 2012-08-17 | 2014-02-20 | Concert Pharmaceuticals, Inc. | Deuterated baricitinib |
| TWI646099B (zh) | 2012-11-01 | 2019-01-01 | 英塞特控股公司 | 作爲ｊａｋ抑制劑之三環稠合噻吩衍生物 |
| RS62867B1 (sr) | 2013-03-06 | 2022-02-28 | Incyte Holdings Corp | Postupci i intermedijeri za dobijanje inhibitora jak |
| HUE033587T2 (hu) | 2013-05-17 | 2017-12-28 | Incyte Corp | Bipirazol-származékok mint JAK inhibitorok |
| SMT202000315T1 (it) * | 2013-08-07 | 2020-07-08 | Incyte Corp | Forme di dosaggio a rilascio prolungato per un inibitore di jak1 |
| AU2014339897A1 (en) * | 2013-10-24 | 2016-04-21 | Abbvie Inc. | JAK1 selective inhibitor and uses thereof |
| KR20160136323A (ko) | 2014-02-28 | 2016-11-29 | 인사이트 코포레이션 | 골수형성이상증후군 치료용 jak1 억제제 |
| MA39987A (fr) | 2014-04-30 | 2017-03-08 | Incyte Corp | Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| UA123633C2 (uk) | 2015-11-03 | 2021-05-05 | Тереванс Байофарма Ар Енд Ді Айпі, Елелсі | Сполуки інгібітору jak-кінази для лікування респіраторного захворювання |
| CN105294699B (zh) * | 2015-12-04 | 2019-06-11 | 上海勋和医药科技有限公司 | 巴瑞替尼的制备方法 |
| MX390005B (es) * | 2016-10-03 | 2025-03-20 | Hangzhou Highlightll Pharmaceutical Co Ltd | Inhibidores selectivos de jak1 novedosos y usos de los mismos. |
| EP3327020A1 (en) * | 2016-11-29 | 2018-05-30 | Sandoz Ag | Citrate salts of a janus kinase (jak) inhibitor |
| WO2018165392A1 (en) | 2017-03-09 | 2018-09-13 | Theravance Biopharma R&D Ip, Llc | Jak inhibitors containing a 4-membered heterocyclic amide |
| WO2018204233A1 (en) | 2017-05-01 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a jak inhibitor compound |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| SG11202007164UA (en) | 2018-01-30 | 2020-08-28 | Incyte Corp | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| KR102925957B1 (ko) | 2018-02-16 | 2026-02-11 | 인사이트 코포레이션 | 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제 |
| SMT202400306T1 (it) | 2018-03-30 | 2024-09-16 | Incyte Corp | Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak. |
| CA3097025A1 (en) | 2018-04-13 | 2019-10-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| CA3117969A1 (en) | 2018-10-31 | 2020-05-07 | Incyte Corporation | Combination therapy for treatment of hematological diseases |
| JP7624922B2 (ja) | 2018-12-19 | 2025-01-31 | インサイト・コーポレイション | 胃腸疾患の治療のためのｊａｋ１経路阻害剤 |
| WO2020181034A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
| US11624751B2 (en) | 2019-03-19 | 2023-04-11 | Incyte Corporation | Biomarkers for vitiligo |
-
2020
- 2020-03-05 WO PCT/US2020/021088 patent/WO2020181034A1/en not_active Ceased
- 2020-03-05 MA MA055201A patent/MA55201A/fr unknown
- 2020-03-05 MX MX2021010545A patent/MX2021010545A/es unknown
- 2020-03-05 US US16/810,045 patent/US11406640B2/en active Active
- 2020-03-05 EP EP25213638.7A patent/EP4691567A3/en active Pending
- 2020-03-05 PH PH1/2021/552130A patent/PH12021552130A1/en unknown
- 2020-03-05 EP EP20713496.6A patent/EP3934651A1/en active Pending
- 2020-03-05 KR KR1020217031644A patent/KR20210137087A/ko active Pending
- 2020-03-05 JP JP2021552624A patent/JP2022524997A/ja active Pending
- 2020-03-05 SG SG11202109563WA patent/SG11202109563WA/en unknown
- 2020-03-05 IL IL285999A patent/IL285999B2/en unknown
- 2020-03-05 AU AU2020232757A patent/AU2020232757B2/en active Active
- 2020-03-05 CN CN202080024215.0A patent/CN114007621A/zh active Pending
- 2020-03-05 EA EA202192426A patent/EA202192426A1/ru unknown
- 2020-03-05 UA UAA202105585A patent/UA130579C2/uk unknown
- 2020-03-05 CA CA3132371A patent/CA3132371A1/en active Pending
-
2021
- 2021-09-02 MX MX2024007081A patent/MX2024007081A/es unknown
-
2022
- 2022-06-30 US US17/854,443 patent/US11896595B2/en active Active
-
2025
- 2025-02-21 JP JP2025026650A patent/JP2025087734A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3934651A1 (en) | 2022-01-12 |
| US11406640B2 (en) | 2022-08-09 |
| AU2020232757A1 (en) | 2021-10-07 |
| IL285999B1 (en) | 2025-09-01 |
| UA130579C2 (uk) | 2026-03-25 |
| WO2020181034A1 (en) | 2020-09-10 |
| JP2025087734A (ja) | 2025-06-10 |
| EP4691567A3 (en) | 2026-04-29 |
| KR20210137087A (ko) | 2021-11-17 |
| PH12021552130A1 (en) | 2022-08-31 |
| CN114007621A (zh) | 2022-02-01 |
| EP4691567A2 (en) | 2026-02-11 |
| US20200281931A1 (en) | 2020-09-10 |
| EA202192426A1 (ru) | 2021-11-15 |
| IL285999A (en) | 2021-10-31 |
| CA3132371A1 (en) | 2020-09-10 |
| AU2020232757B2 (en) | 2025-09-11 |
| JP2022524997A (ja) | 2022-05-11 |
| IL285999B2 (en) | 2026-01-01 |
| US20220331325A1 (en) | 2022-10-20 |
| MX2024007081A (es) | 2024-06-21 |
| MX2021010545A (es) | 2021-11-17 |
| US11896595B2 (en) | 2024-02-13 |
| MA55201A (fr) | 2022-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285999A (en) | jak1 inhibitor pathway for the treatment of impaired chronic lung allograft function | |
| IL276725A (en) | JAK1 pathway inhibitors for the treatment of cytokine-related disorders | |
| IL292690A (en) | mrgprx2 antagonists for the treatment of inflammatory disorders | |
| IL284034A (en) | JAK1 pathway inhibitors for the treatment of gastrointestinal disease | |
| IL292642B1 (en) | RAS inhibitors | |
| SMT202500146T1 (it) | Inibitori di parp1 | |
| IL291453A (en) | Dosage forms for tyk2 inhibitors | |
| IL287717A (en) | Pyrrolopyridines are converted as jak inhibitors | |
| IL290011B1 (en) | Ezh2 inhibition in combination therapies for cancer treatment | |
| IL279260A (en) | KDM1A inhibitors for the treatment of diseases | |
| IL287902A (en) | Methods of administering certain vmat2 inhibitors | |
| IL308476A (en) | Inhibitors of the menin-mil interaction | |
| IL282007A (en) | Medicine to treat chronic cough | |
| PT3956322T (pt) | Inibidor seletivo de cinase jak1 | |
| IL308216A (en) | Jak1 pathway inhibitors for the treatment of prurigo nodularis | |
| IL291785A (en) | 6,1- Naphthyridine-converted inhibitors of cdk5 | |
| IL281599A (en) | TYK2 kinase inhibitors | |
| PT3645735T (pt) | Métodos e composições para prever disfunção crónica de aloenxerto pulmonar | |
| HK40067155A (en) | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction | |
| GB201814067D0 (en) | Compounds for the inhibition of cyclophilins | |
| IL316410A (en) | Blumosodil for the treatment of chronic pulmonary allograft dysfunction | |
| IL286533A (en) | Compounds for use in the treatment of adcy5-related dyskinesia | |
| IL282739A (en) | Compounds and methods for treating smooth muscle dysfunction | |
| SG10201902000YA (en) | Isthmin 1 for treatment of lung inflammation | |
| HK40044028A (en) | Jak1 pathway inhibitors for the treatment of cytokine-related disorders |